Skip to main content
OpenTrials
Completed

NCT Number: NCT00244413

Characteristics of Nondystrophic Myotonias

Nondystrophic myotonias (NDM) are muscle disorders caused by genetic abnormalities in certain muscle cell membrane proteins. Individuals with NDM experience limited muscle relaxation, which causes pain, weakness, and impaired physical activity. The purpose of this study is to better characterize the clinical features and symptoms of NDM.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Nondystrophic myotonias are muscle disorders caused by abnormal muscle cell membrane proteins that affect the control of muscle fiber contraction. These disorders are extremely rare, and little is known about how to best treat the various subtypes of NDM. The purpose of this study is to characterize the clinical features and symptoms of NDM as well as to pair this data with specific NDM subtypes. In turn, this may lead to the development of improved treatments. The study will also establish clinical endpoints for use in future studies.

This multi-center observational study will involve both a cross-sectional data analysis and a prospective longitudinal analysis. Participants will initially attend a one-day outpatient study visit. Various baseline measurements will be collected, including demographics, medical history, and quality of life measures. Blood samples will be taken to evaluate laboratory values and genetic factors. Participants will undergo manual muscle testing (MMT), clinical myotonia assessments, and functional movement assessments. Routine nerve conduction studies and electromyography (EMG) will also be performed in order to test for the presence of myotonia in specific muscles. Annual follow-up evaluations will occur 1 and 2 years following the first study visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical symptoms or signs suggestive of myotonia
  • Presence of myotonic potentials on electromyography (EMG)
  • Persistence of symptoms and signs after discontinuation of medications that produce myotonia; such medications include fibric acid derivatives, hydroxymethylglutaryl CoA reductase inhibitors, chloroquine, and colchicine
  • Absence of features suggestive of myotonic dystrophy, including ptosis, temporal wasting, mandibular weakness, cataracts occurring before age 50, and evidence of multisystem defects (cardiac conduction defects, hypogonadism)

Exclusion criteria

  • Any other neurologic condition that might affect the assessment of the study measurements

Treatment and study plan

Primary outcomes

  1. Examine the frequency applicable events related to Nondystrophic Myotonia

    Time frame: Baseline - 3 yrs

    We will measure by an interactive voice response to measure stiffness, pain, weakness, and fatigue.

Sponsors and collaborators

Lead sponsor

Richard Barohn, MD

Other

Collaborators

  • Office of Rare Diseases (ORD)
  • Rare Diseases Clinical Research Network

Registry information

Official study title

Nondystrophic Myotonias: Genotype-phenotype Correlation and Longitudinal Study

Important dates

Study start
2006
Primary completion
2012
Study completion
2012
First posted
Oct 26, 2005
Registry last updated
Mar 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.